Entrada Therapeutics (TRDA) Expected to Announce Quarterly Earnings on Wednesday

Entrada Therapeutics (NASDAQ:TRDA) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($1.0493) per share and revenue of $2.2340 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The business had revenue of $0.88 million for the quarter, compared to the consensus estimate of $2.92 million. On average, analysts expect Entrada Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $6.79 on Monday. The firm has a market capitalization of $263.59 million, a price-to-earnings ratio of -1.70 and a beta of -0.26. The company’s 50 day simple moving average is $6.83 and its 200 day simple moving average is $9.84. Entrada Therapeutics has a fifty-two week low of $4.93 and a fifty-two week high of $16.45.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on TRDA shares. HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. Guggenheim lowered their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Roth Capital set a $10.00 price objective on Entrada Therapeutics in a research report on Friday, May 8th. Finally, Oppenheimer increased their target price on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research note on Monday, April 6th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $17.50.

Insider Activity

In related news, Director Bernhardt G. Zeiher acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $5.86 per share, with a total value of $29,300.00. Following the acquisition, the director owned 5,000 shares in the company, valued at $29,300. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Entrada Therapeutics

A number of large investors have recently added to or reduced their stakes in TRDA. Millennium Management LLC raised its holdings in shares of Entrada Therapeutics by 391.2% in the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares during the period. Citadel Advisors LLC lifted its stake in Entrada Therapeutics by 234.5% in the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock valued at $1,947,000 after purchasing an additional 235,384 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in Entrada Therapeutics by 115.3% during the third quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock worth $1,670,000 after purchasing an additional 154,143 shares during the period. BNP Paribas Financial Markets grew its holdings in Entrada Therapeutics by 4,767.4% during the third quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock worth $860,000 after purchasing an additional 145,167 shares during the period. Finally, Algert Global LLC acquired a new position in Entrada Therapeutics during the third quarter worth approximately $753,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.